New biosimilars for Janssen Biotech, Inc.’s Remicade (infliximab) have helped to moderate costs for Crohn’s disease as they’ve launched over the last two years, but plans still rely on utilization management strategies, including site-of-service programs, to keep the cost of treating the condition under control, experts say.
- People on the Move
- Medicare and Medicaid
- Datapoint, Medicare and Medicaid
- Abstract, Health Plans
- Datapoint, Drug Benefits, Medicare and Medicaid